{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:05:40Z","timestamp":1771308340686,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFA1800403"],"award-info":[{"award-number":["2023YFA1800403"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12272-026-01594-0","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T04:48:49Z","timestamp":1770094129000},"page":"174-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of a potent STAT3 inhibitor WR-S-647 for the treatment of ADPKD"],"prefix":"10.1007","volume":"49","author":[{"given":"Zhaoyong","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangrui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangrui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5311-842X","authenticated-orcid":false,"given":"Jiemin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-4825","authenticated-orcid":false,"given":"Dong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-7980","authenticated-orcid":false,"given":"Yihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"1","key":"1594_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/07391102.2023.2199081","volume":"42","author":"C Ala","year":"2024","unstructured":"Ala C, Joshi RP, Gupta P, Ramalingam S, Sankaranarayanan M (2024) Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches. J Biomol Struct Dyn 42(1):261\u2013273. https:\/\/doi.org\/10.1080\/07391102.2023.2199081","journal-title":"J Biomol Struct Dyn"},{"issue":"8","key":"1594_CR2","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1021\/acs.jmedchem.5c00614","volume":"68","author":"JK Awalt","year":"2025","unstructured":"Awalt JK, Ooi ZK, Ashton TD, Mansouri M, Calic PPS, Zhou Q, Vasanthan S, Lee S, Loi K, Jarman KE, Penington JS, Qiu D, Zhang X, Lehane AM, Mao EY, Gancheva MR, Wilson DW, Giannangelo C, MacRaild CA, Creek DJ, Yeo T, Sheth T, Fidock DA, Churchyard A, Baum J, Famodimu MT, Delves MJ, Kristan M, Stewart L, Sutherland CJ, Coyle R, Jagoe H, Lee MCS, Chowdury M, de Koning-Ward TF, Baud D, Brand S, Jackson PF, Cowman AF, Dans MG, Sleebs BE (2025) Optimization and characterization of N-acetamide indoles as antimalarials that target PfATP4. J Med Chem 68(8):8933\u20138966. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00614","journal-title":"J Med Chem"},{"issue":"13","key":"1594_CR3","doi-asserted-by":"publisher","first-page":"9295","DOI":"10.1021\/acs.jmedchem.2c00567","volume":"65","author":"X Cao","year":"2022","unstructured":"Cao X, Wang P, Yuan H, Zhang H, He Y, Fu K, Fang Q, Liu H, Su L, Yin L, Xu P, Xie Y, Xiong X, Wang J, Zhu X, Guo D (2022) Benzodiazepine derivatives as potent vasopressin V(2) receptor antagonists for the treatment of autosomal dominant kidney disease. J Med Chem 65(13):9295\u20139311. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00567","journal-title":"J Med Chem"},{"issue":"11","key":"1594_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2215\/cjn.03960318","volume":"13","author":"FT Chebib","year":"2018","unstructured":"Chebib FT, Torres VE (2018) Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 13(11):1765\u20131776. https:\/\/doi.org\/10.2215\/cjn.03960318","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10174","key":"1594_CR5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s0140-6736(18)32782-x","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD (2019) Autosomal dominant polycystic kidney disease. Lancet 393(10174):919\u2013935. https:\/\/doi.org\/10.1016\/s0140-6736(18)32782-x","journal-title":"Lancet"},{"issue":"13","key":"1594_CR6","doi-asserted-by":"publisher","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","volume":"64","author":"J Dong","year":"2021","unstructured":"Dong J, Cheng XD, Zhang WD, Qin JJ (2021) Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation. J Med Chem 64(13):8884\u20138915. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00629","journal-title":"J Med Chem"},{"issue":"4","key":"1594_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317344121","volume":"121","author":"BI Fedeles","year":"2024","unstructured":"Fedeles BI, Bhardwaj R, Ishikawa Y, Khumsubdee S, Krappitz M, Gubina N, Volpe I, Andrade DC, Westergerling P, Staudner T, Campolo J, Liu SS, Dong K, Cai Y, Rehman M, Gallagher AR, Ruchirawat S, Croy RG, Essigmann JM, Fedeles SV, Somlo S (2024) A synthetic agent ameliorates polycystic kidney disease by promoting apoptosis of cystic cells through increased oxidative stress. Proc Natl Acad Sci U S A 121(4):e2317344121. https:\/\/doi.org\/10.1073\/pnas.2317344121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1594_CR8","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.1016\/j.apsb.2024.08.031","volume":"14","author":"Z Fu","year":"2024","unstructured":"Fu Z, Wu T, Gao C, Wang L, Zhang Y, Shi C (2024) AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer. Acta Pharm Sin B 14(12):5305\u20135320. https:\/\/doi.org\/10.1016\/j.apsb.2024.08.031","journal-title":"Acta Pharm Sin B"},{"issue":"24","key":"1594_CR9","doi-asserted-by":"publisher","first-page":"16917","DOI":"10.1021\/acs.jmedchem.3c01639","volume":"66","author":"H Gu","year":"2023","unstructured":"Gu H, Zhang T, Guan T, Wu M, Li S, Li Y, Guo M, Zhang L, Peng Y, Mi D, Liu M, Yi Z, Chen Y (2023) Discovery of a highly potent and selective MYOF inhibitor with improved water solubility for the treatment of gastric cancer. J Med Chem 66(24):16917\u201316938. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01639","journal-title":"J Med Chem"},{"issue":"3","key":"1594_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.apsb.2024.12.035","volume":"15","author":"JH Han","year":"2025","unstructured":"Han JH, Heo JB, Lee HW, Park MH, Choi J, Yun EJ, Lee S, Song GY, Myung CS (2025) Novel carbazole attenuates vascular remodeling through STAT3\/CIAPIN1 signaling in vascular smooth muscle cells. Acta Pharm Sin B 15(3):1463\u20131479. https:\/\/doi.org\/10.1016\/j.apsb.2024.12.035","journal-title":"Acta Pharm Sin B"},{"issue":"22","key":"1594_CR11","doi-asserted-by":"publisher","first-page":"15487","DOI":"10.1021\/acs.jmedchem.2c01554","volume":"65","author":"P He","year":"2022","unstructured":"He P, Bian A, Miao Y, Jin W, Chen H, He J, Li L, Sun Y, Ye J, Liu M, Yi Z, Zhou W, Chen Y (2022a) Discovery of a highly potent and orally bioavailable STAT3 dual phosphorylation inhibitor for pancreatic cancer treatment. J Med Chem 65(22):15487\u201315511. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01554","journal-title":"J Med Chem"},{"issue":"19","key":"1594_CR12","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.1021\/acs.jmedchem.2c00413","volume":"65","author":"P He","year":"2022","unstructured":"He P, Miao Y, Sun Y, Bian A, Jin W, Chen H, Ye J, He J, Peng Y, Gu H, Liu M, Yi Z, Chen Y (2022b) Discovery of a novel potent STAT3 inhibitor HP590 with dual p-Tyr705\/Ser727 inhibitory activity for gastric cancer treatment. J Med Chem 65(19):12650\u201312674. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00413","journal-title":"J Med Chem"},{"issue":"9","key":"1594_CR13","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1021\/acs.jmedchem.2c01844","volume":"66","author":"P He","year":"2023","unstructured":"He P, Feng J, Xia X, Sun Y, He J, Guan T, Peng Y, Zhang X, Liu M, Pang X, Chen Y (2023) Discovery of a potent and oral available complex I OXPHOS inhibitor that abrogates tumor growth and circumvents MEKi resistance. J Med Chem 66(9):6047\u20136069. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01844","journal-title":"J Med Chem"},{"issue":"11","key":"1594_CR14","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.1021\/acs.jmedchem.4c00268","volume":"67","author":"N Iraci","year":"2024","unstructured":"Iraci N, Carotenuto L, Ciaglia T, Belperio G, Di Matteo F, Mosca I, Carleo G, Giovanna Basilicata M, Ambrosino P, Turcio R, Puzo D, Pepe G, Gomez-Monterrey I, Soldovieri MV, Di Sarno V, Campiglia P, Miceli F, Bertamino A, Ostacolo C, Taglialatela M (2024) In silico assisted identification, synthesis, and in vitro pharmacological characterization of potent and selective blockers of the epilepsy-associated KCNT1 channel. J Med Chem 67(11):9124\u20139149. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00268","journal-title":"J Med Chem"},{"issue":"10","key":"1594_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04248-9","volume":"12","author":"A Jamadar","year":"2021","unstructured":"Jamadar A, Suma SM, Mathew S, Fields TA, Wallace DP, Calvet JP, Rao R (2021) The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death Dis 12(10):947. https:\/\/doi.org\/10.1038\/s41419-021-04248-9","journal-title":"Cell Death Dis"},{"issue":"42","key":"1594_CR16","doi-asserted-by":"publisher","first-page":"12118","DOI":"10.1021\/acs.jmedchem.4c00878","volume":"67","author":"F Jiang","year":"2024","unstructured":"Jiang F, Yu M, Liang Y, Ding K, Wang Y (2024) Discovery of novel diaryl-substituted fused heterocycles targeting katanin and tubulin with potent antitumor and antimultidrug resistance efficacy. J Med Chem 67(42):12118\u201312142. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00878","journal-title":"J Med Chem"},{"issue":"9","key":"1594_CR17","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1021\/acs.jmedchem.2c00004","volume":"65","author":"W Jin","year":"2022","unstructured":"Jin W, Zhang T, Zhou W, He P, Sun Y, Hu S, Chen H, Ma X, Peng Y, Yi Z, Liu M, Chen Y (2022) Discovery of 2-amino-3-cyanothiophene derivatives as potent STAT3 inhibitors for the treatment of osteosarcoma growth and metastasis. J Med Chem 65(9):6710\u20136728. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00004","journal-title":"J Med Chem"},{"key":"1594_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117332","volume":"287","author":"W Jin","year":"2025","unstructured":"Jin W, Zhang Y, Wang B, Kang Z, Li H, Song J, Chen Y, Xiong H, Chen J (2025) Structural optimization and characterization of highly potent and selective STAT3 inhibitors for the treatment of triple negative breast cancer. Eur J Med Chem 287:117332. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117332","journal-title":"Eur J Med Chem"},{"issue":"7","key":"1594_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2024.110447","volume":"36","author":"Z Kang","year":"2025","unstructured":"Kang Z, Li S, Li Y, Song J, Peng Y, Chen Y (2025) Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: an updated review (from 2022 to 2024). Chin Chem Lett 36(7):110447. https:\/\/doi.org\/10.1016\/j.cclet.2024.110447","journal-title":"Chin Chem Lett"},{"issue":"23","key":"1594_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202310208","volume":"11","author":"J Li","year":"2024","unstructured":"Li J, Qin Z, Li Y, Huang B, Xiao Q, Chen P, Luo Y, Zheng W, Zhang T, Zhang Z (2024) Phosphorylation of IDH1 facilitates progestin resistance in endometrial cancer. Adv Sci 11(23):e2310208. https:\/\/doi.org\/10.1002\/advs.202310208","journal-title":"Adv Sci"},{"issue":"1","key":"1594_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07535-x","volume":"16","author":"S Li","year":"2025","unstructured":"Li S, Wang X, Huang J, Cao X, Liu Y, Bai S, Zeng T, Chen Q, Li C, Lu C, Yang H (2025) Decoy-PROTAC for specific degradation of \u201cUndruggable\u201d STAT3 transcription factor. Cell Death Dis 16(1):197. https:\/\/doi.org\/10.1038\/s41419-025-07535-x","journal-title":"Cell Death Dis"},{"issue":"4","key":"1594_CR22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.molmed.2023.01.005","volume":"29","author":"L Luo","year":"2023","unstructured":"Luo L, Roy S, Li L, Ma M (2023) Polycystic kidney disease: novel insights into polycystin function. Trends Mol Med 29(4):268\u2013281. https:\/\/doi.org\/10.1016\/j.molmed.2023.01.005","journal-title":"Trends Mol Med"},{"issue":"1","key":"1594_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05785-5","volume":"22","author":"J Lv","year":"2024","unstructured":"Lv J, Lan B, Fu L, He C, Zhou W, Wang X, Zhou C, Mao Z, Chen Y, Mei C, Xue C (2024) EZH2 inhibition or genetic ablation suppresses cyst growth in autosomal dominant polycystic kidney disease. J Transl Med 22(1):979. https:\/\/doi.org\/10.1186\/s12967-024-05785-5","journal-title":"J Transl Med"},{"issue":"1","key":"1594_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-biochem-030222-120000","volume":"93","author":"JM Paggi","year":"2024","unstructured":"Paggi JM, Pandit A, Dror RO (2024) The art and science of molecular docking. Annu Rev Biochem 93(1):389\u2013410. https:\/\/doi.org\/10.1146\/annurev-biochem-030222-120000","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"1594_CR25","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/s41598-019-41106-3","volume":"9","author":"F Patera","year":"2019","unstructured":"Patera F, Cudzich-Madry A, Huang Z, Fragiadaki M (2019) Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis. Sci Rep 9(1):4491. https:\/\/doi.org\/10.1038\/s41598-019-41106-3","journal-title":"Sci Rep"},{"issue":"4","key":"1594_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1681\/asn.2015010047","volume":"27","author":"CS Pinto","year":"2016","unstructured":"Pinto CS, Raman A, Reif GA, Magenheimer BS, White C, Calvet JP, Wallace DP (2016) Phosphodiesterase isoform regulation of cell proliferation and fluid secretion in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27(4):1124\u20131134. https:\/\/doi.org\/10.1681\/asn.2015010047","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1594_CR27","doi-asserted-by":"publisher","first-page":"9101","DOI":"10.1021\/acs.jmedchem.5c00279","volume":"68","author":"MJ Rawling","year":"2025","unstructured":"Rawling MJ, Ray-Sinha A, Bestwick M, Carter MK, Chahal SK, Chalmers AJ, Elsey DJ, Giddings A, Gold J, Henderson SH, MacGregor C, Malcolm A, Ortega F, Phelan A, Savory ED, Schwartz AC, Stevenson NG, Turner EL, Vass M, Wright JA, Watson C (2025) Discovery of a potent, selective, and brain-penetrant checkpoint kinase 1 inhibitor, BEN-28010, for the treatment of glioblastoma. J Med Chem 68(9):9101\u20139125. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00279","journal-title":"J Med Chem"},{"issue":"6","key":"1594_CR28","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.3390\/ijms23063317","volume":"23","author":"J Reiterov\u00e1","year":"2022","unstructured":"Reiterov\u00e1 J, Tesa\u0159 V (2022) Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment. Int J Mol Sci 23(6):3317. https:\/\/doi.org\/10.3390\/ijms23063317","journal-title":"Int J Mol Sci"},{"key":"1594_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115355","volume":"207","author":"Y Ren","year":"2023","unstructured":"Ren Y, Zhu X, Fu K, Zhang H, Zhao W, Lin Y, Fang Q, Wang J, Chen Y, Guo D (2023) Inhibition of deubiquitinase USP28 attenuates cyst growth in autosomal dominant polycystic kidney disease. Biochem Pharmacol 207:115355. https:\/\/doi.org\/10.1016\/j.bcp.2022.115355","journal-title":"Biochem Pharmacol"},{"issue":"Pt 2","key":"1594_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117222","volume":"242","author":"Y Ren","year":"2025","unstructured":"Ren Y, Pan Y, Zhu X, Li L, Zhao W, Fu K, Chen Y, Sun Y, Guo D (2025) Targeting TRAF6 inhibits cystogenesis in autosomal dominant polycystic kidney disease. Biochem Pharmacol 242(Pt 2):117222. https:\/\/doi.org\/10.1016\/j.bcp.2025.117222","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1594_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104359","volume":"25","author":"JK Scholz","year":"2022","unstructured":"Scholz JK, Kraus A, L\u00fcder D, Skoczynski K, Schiffer M, Grampp S, Sch\u00f6del J, Buchholz B (2022) Loss of polycystin-1 causes cAMP-dependent switch from tubule to cyst formation. iScience 25(6):104359. https:\/\/doi.org\/10.1016\/j.isci.2022.104359","journal-title":"iScience"},{"issue":"8","key":"1594_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083692","volume":"26","author":"X Shi","year":"2025","unstructured":"Shi X, Kuai L, Xu D, Qiao Y, Chen Y, Di B, Xu P (2025) Surface plasmon resonance (SPR) for the binding kinetics analysis of synthetic cannabinoids: advancing CB1 receptor interaction studies. Int J Mol Sci 26(8):3692. https:\/\/doi.org\/10.3390\/ijms26083692","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1594_CR33","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","volume":"20","author":"A Takakura","year":"2011","unstructured":"Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA, Zhou J (2011) Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 20(21):4143\u20134154. https:\/\/doi.org\/10.1093\/hmg\/ddr338","journal-title":"Hum Mol Genet"},{"issue":"19","key":"1594_CR34","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1073\/pnas.1103816108","volume":"108","author":"JJ Talbot","year":"2011","unstructured":"Talbot JJ, Shillingford JM, Vasanth S, Doerr N, Mukherjee S, Kinter MT, Watnick T, Weimbs T (2011) Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A 108(19):7985\u20137990. https:\/\/doi.org\/10.1073\/pnas.1103816108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1594_CR35","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1681\/asn.2013091026","volume":"25","author":"JJ Talbot","year":"2014","unstructured":"Talbot JJ, Song X, Wang X, Rinschen MM, Doerr N, LaRiviere WB, Schermer B, Pei YP, Torres VE, Weimbs T (2014) The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol 25(8):1737\u20131748. https:\/\/doi.org\/10.1681\/asn.2013091026","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1594_CR36","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/asn.2016111232","volume":"28","author":"V Tesar","year":"2017","unstructured":"Tesar V, Ciechanowski K, Pei Y, Barash I, Shannon M, Li R, Williams JH, Levisetti M, Arkin S, Serra A (2017) Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 28(11):3404\u20133413. https:\/\/doi.org\/10.1681\/asn.2016111232","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"1594_CR37","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501605R","volume":"39","author":"J Wu","year":"2025","unstructured":"Wu J, Cheng AS, Weimbs T, Harris PC, Zhou JX, Li X (2025) GLP-1RA semaglutide delays the progression of ADPKD through regulation of glycolysis, mitochondria function and ketosis. FASEB J 39(16):e70944. https:\/\/doi.org\/10.1096\/fj.202501605R","journal-title":"FASEB J"},{"issue":"5","key":"1594_CR38","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.apsb.2025.03.041","volume":"15","author":"H Xin","year":"2025","unstructured":"Xin H, Zhao Z, Guo S, Tian R, Ma L, Yang Y, Zhao L, Wang G, Li B, Hu X, Song Y, Wang G (2025) Targeting the JAK2-STAT3-UCHL3-ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer. Acta Pharm Sin B 15(5):2529\u20132544. https:\/\/doi.org\/10.1016\/j.apsb.2025.03.041","journal-title":"Acta Pharm Sin B"},{"issue":"25","key":"1594_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414587","volume":"12","author":"C Xuan","year":"2025","unstructured":"Xuan C, Chen D, Zhang S, Li C, Fang Q, Chen D, Liu J, Jiang X, Zhang Y, Shen W, Cai G, Chen X, Li P (2025) Isoquercitrin alleviates diabetic nephropathy by inhibiting STAT3 phosphorylation and dimerization. Adv Sci (Weinh) 12(25):e2414587. https:\/\/doi.org\/10.1002\/advs.202414587","journal-title":"Adv Sci (Weinh)"},{"issue":"23","key":"1594_CR40","doi-asserted-by":"publisher","first-page":"15770","DOI":"10.1021\/acs.jmedchem.2c01334","volume":"65","author":"B Yang","year":"2022","unstructured":"Yang B, Zhang H, Li N, Gao L, Jiang H, Kan W, Yuan H, Li J, Zhao D, Xiong B, Zhou Y, Guo D, Liu T (2022) Discovery of novel N-(5-(pyridin-3-yl)-1H-indazol-3-yl)benzamide derivatives as potent cyclin-dependent kinase 7 inhibitors for the treatment of autosomal dominant polycystic kidney disease. J Med Chem 65(23):15770\u201315788. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01334","journal-title":"J Med Chem"},{"issue":"5","key":"1594_CR41","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1021\/acs.jmedchem.4c02128","volume":"68","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu H, Yuan H, Lyu K, Zhong H, Li Y, Cao D, Zhao W, Zhang H, Xiong B, Chen D, Guo D (2025) Design of selective BRD4 inhibitors for the treatment of autosomal dominant polycystic kidney disease. J Med Chem 68(5):5257\u20135274. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02128","journal-title":"J Med Chem"},{"issue":"7","key":"1594_CR42","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/hmg\/ddac273","volume":"32","author":"W Yu","year":"2023","unstructured":"Yu W, Wang G, Li LX, Zhang H, Gui X, Zhou JX, Calvet JP, Li X (2023) Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD. Hum Mol Genet 32(7):1114\u20131126. https:\/\/doi.org\/10.1093\/hmg\/ddac273","journal-title":"Hum Mol Genet"},{"issue":"11","key":"1594_CR43","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1021\/acs.jmedchem.2c00011","volume":"65","author":"H Zhang","year":"2022","unstructured":"Zhang H, Yan W, Sun Y, Yuan H, Su L, Cao X, Wang P, Xu Z, Hu Y, Wang Z, Wang Y, Fu K, Sun Y, Chen Y, Cheng J, Guo D (2022) Long residence time at the vasopressin V(2) receptor translates into superior inhibitory effects in ex vivo and in vivo models of autosomal dominant polycystic kidney disease. J Med Chem 65(11):7717\u20137728. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00011","journal-title":"J Med Chem"},{"issue":"2","key":"1594_CR44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.apsb.2022.08.014","volume":"13","author":"D Zhao","year":"2023","unstructured":"Zhao D, Zhang J, Zhang L, Wu Q, Wang Y, Zhang W, Xiao Y, Chen J, Zhan Q (2023) PAFR\/Stat3 axis maintains the symbiotic ecosystem between tumor and stroma to facilitate tumor malignancy. Acta Pharm Sin B 13(2):694\u2013708. https:\/\/doi.org\/10.1016\/j.apsb.2022.08.014","journal-title":"Acta Pharm Sin B"},{"key":"1594_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01664-x","author":"DD Zhong","year":"2025","unstructured":"Zhong DD, Hu C, Zhao LL, Shen Y, Zhang RM, Liu Y, Liu BH, Su W, Yang BX, Xiong H, Guo D, Sun D, Zou YY, Sun Y (2025) Inhibiting mPGES-2 impedes renal cyst growth in mice with polycystic kidney disease. Acta Pharmacol Sin. https:\/\/doi.org\/10.1038\/s41401-025-01664-x","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"1594_CR46","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.kint.2023.02.010","volume":"103","author":"JX Zhou","year":"2023","unstructured":"Zhou JX, Torres VE (2023) Drug repurposing in autosomal dominant polycystic kidney disease. Kidney Int 103(5):859\u2013871. https:\/\/doi.org\/10.1016\/j.kint.2023.02.010","journal-title":"Kidney Int"},{"issue":"2","key":"1594_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.kint.2024.04.017","volume":"106","author":"JX Zhou","year":"2024","unstructured":"Zhou JX, Li LX, Zhang H, Agborbesong E, Harris PC, Calvet JP, Li X (2024) DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age acceleration in autosomal dominant polycystic kidney disease. Kidney Int 106(2):258\u2013272. https:\/\/doi.org\/10.1016\/j.kint.2024.04.017","journal-title":"Kidney Int"},{"key":"1594_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09000-3","author":"J Zhou","year":"2025","unstructured":"Zhou J, Tison K, Zhou H, Bai L, Acharyya RK, McEachern D, Metwally H, Wang Y, Pitter M, Choi JE, Vatan L, Liao P, Yu J, Lin H, Jiang L, Wei S, Gao X, Grove S, Parolia A, Cieslik M, Kryczek I, Green MD, Lin JX, Chinnaiyan AM, Leonard WJ, Wang S, Zou W (2025) STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature. https:\/\/doi.org\/10.1038\/s41586-025-09000-3","journal-title":"Nature"},{"issue":"1","key":"1594_CR49","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1039\/c7fo01253e","volume":"9","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Teng T, Wang H, Guo H, Du L, Yang B, Yin X, Sun Y (2018) Quercetin inhibits renal cyst growth in vitro and via parenteral injection in a polycystic kidney disease mouse model. Food Funct 9(1):389\u2013396. https:\/\/doi.org\/10.1039\/c7fo01253e","journal-title":"Food Funct"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01594-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-026-01594-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-026-01594-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:14:44Z","timestamp":1771305284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-026-01594-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1007\/s12272-026-01594-0","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}